Search clinical trials for: Insulin, Long-Acting and Insulin

Total 99958 results

Novo Nordisk A/S

Completed

Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily (BOOST®)

Diabetes Mellitus, Type 2 | Diabetes

United States, Malaysia, Germany, Algeria, Turkey
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir and Insulin Aspart in 2 Separate Injections Twice Daily to Extemporaneous Mixing Injection Regimen Twice Daily - The Paediatric Mixing Trial (MIXING)

Diabetes | Diabetes Mellitus, Type 1

France
Albert Einstein College of Medicine
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

New Onset Type 1 Diabetes: Role of Exenatide

Type 1 Diabetes

United States
Novo Nordisk A/S

Completed

A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes

Healthy | Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.

Diabetes Mellitus, Type 2 | Diabetes

Turkey
Tulane University Health Sciences Center

Completed

Comparison of Insulins Aspart and Lispro in Insulin Pumps

Type 1 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Russian Federation, Serbia, Turkey, Algeria, Czechia
Profil Institut für Stoffwechselforschung GmbH
Sanofi

Completed

Expanded PK and PD of Insulin Glulisine Versus Insulin Aspart in Healthy Volunteers

Diabetes

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Spain, Finland, Germany
Novo Nordisk A/S

Completed

Comparison of Two NN1250 Formulations in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

China
Tonghua Dongbao Pharmaceutical Co.,Ltd

Completed

A Phase III Study of Insulin Aspart Injection to Evaluate the Efficacy and Safety

Diabetes

China
Sanofi

Completed

Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients

Type 1 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
CPEX Pharmaceuticals Inc.

Withdrawn

Intranasal Insulin and Its Effect on Postprandial Metabolism in Comparison to Subcutaneous Insulin

Type 1 Diabetes Mellitus
Novo Nordisk A/S

Completed

Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, United Kingdom, Denmark, Netherlands, Norway, South Africa, Finland, France, Spain, Former Serbia and Montenegro, Sweden
Novo Nordisk A/S

Completed

Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen (Full STEP™)

Diabetes Mellitus, Type 2 | Diabetes

United States, France, Argentina, Macedonia, The Former Yugoslav Republic of, Slovenia, Canada, Brazil
Rush University Medical Center

Terminated

Carbohydrate Consumption as a Factor in Aspart Dosing (CARB)

Diabetes

United States
Novo Nordisk A/S

Completed

Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin (SIT2MIX)

Diabetes Mellitus, Type 2 | Diabetes

Korea, Republic of, India, Malaysia, Turkey, Argentina, Greece, Australia, Portugal, Thailand, Brazil
Aarhus University Hospital
Novo Nordisk A/S

Completed

Changes of the Infusion Rate in Insulin Pump Treatment

Diabetes

Denmark
Novo Nordisk A/S

Completed

Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine (BOOST®)

Diabetes Mellitus, Type 2 | Diabetes

United States, Malaysia, Germany, Algeria, Turkey
IKFE Institute for Clinical Research and Development

Completed

Effect of Insulin Glulisine vs Regular Human Insulin on Postprandial Endothelial Function in Type 2 Diabetes

Diabetes Mellitus

Germany
Novo Nordisk A/S

Completed

Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Wake Forest University Health Sciences
National Institute on Aging (NIA); General Electric

Completed

Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart (SNIFF-Quick)

Mild Cognitive Impairment | Alzheimer's Disease

United States
Novo Nordisk A/S

Completed

A Trial Investigating the Absolute Bioavailability of Insulin Degludec in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

A Trial Assessing Changes in Blood Sugar and the Number of Periods Where Supplementation of Carbohydrate is Needed to Treat Low Blood Sugar, During Two Different Treatment Regimens of NN1250 in Type 1 Diabetics

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Characteristics of Explorative Formulations of Insulin Degludec and IDegAsp 50 in Healthy Japanese Subjects

Healthy | Diabetes

Germany
University of Aarhus

Completed

Pharmacokinetics of IAsp Following CSII in Patients With T1DM

Type 1 Diabetes Mellitus

Denmark
Diasome Pharmaceuticals

Completed

Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec

Diabetes Mellitus, Type 1

United States
LMC Diabetes & Endocrinology Ltd.
Sanofi

Completed

Long Acting Insulin Glargine Titration Web Tool (LTHome) vs Enhanced Usual Therapy of Glargine Titration (INNOVATE)

Type 2 Diabetes Mellitus

Canada
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Trial Investigating the NN1250 Concentration-time Curve in Subjects With Various Degrees of Renal Impairment and in Subjects With Normal Renal Function

Healthy | Diabetes

Hungary
Emory University

Completed

Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Completed

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, India, South Africa, Canada
Emory University

Completed

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

Hyperglycemia

United States
Novo Nordisk A/S

Completed

Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Canada, Australia
Novo Nordisk A/S

Completed

Efficacy and Safety of Three Times a Day BIAsp-70 Compared to Two Times a Day BIAsp-30 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy (INITIATE)

Diabetes Mellitus, Type 2 | Diabetes

United States
Sunshine Lake Pharma Co., Ltd.

Completed

A Clinical Study Comparing the Pharmacokinetics and Pharmacodynamic Characteristics of Insulin Degludec Injection (RD15003) and Insulin Degludec Injection (Tresiba®) in Healthy Subjects

Type 2 Diabetes

China
Novo Nordisk A/S

Completed

An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Macedonia, The Former Yugoslav Republic of
Novo Nordisk A/S

Completed

Safety, Pharmacokinetics and Pharmacodynamics of Two IDegAsp (One Explorative) Preparations and Two Insulin Degludec (One Explorative) Preparations in Japanese Subjects

Healthy | Diabetes

Japan
Novo Nordisk A/S

Terminated

Safety and Efficacy of Inhaled Insulin in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Israel, Italy, United Kingdom, Denmark, Spain, Singapore, Taiwan, Germany, France, Hong Kong, Brazil
Ain Shams University

Completed

Long Acting Insulin Versus Multiple Dose Regimen for Control of Gestational Diabetes Mellitus

Long Acting Insulin in Control of Gestational Diabetes Mellitus

Egypt
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

India, Israel, Russian Federation, United Kingdom, Taiwan, Argentina, Finland, Hungary, Macedonia, The Former Yugoslav Republic of, Malaysia, Mexico, Norway, Serbia, South Africa
Amphastar Pharmaceuticals, Inc.

Completed

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers

Pharmacokinetics | Pharmacodynamics

United States
Novo Nordisk A/S

Completed

Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Beijing Hospital

Not yet recruiting

Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM

Type 2 Diabetes Mellitus

China

3

Subscribe